Supplementary Information

Enantioselective construction of trifluoromethylated quaternary stereocenters via Rh-catalyzed asymmetric dehydrated arylation of unprotected hemiaminals

Yu-Tuo Sun,^a Dong-Xing Zhu,^a Xiaofeng Rao,^b and Ming-Hua Xu* ^{a,b}

 ^aState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and School of Pharmacy, University of Chinese Academy of Sciences, 555 Zu-chongzhi Road, Shanghai 201203, China.
 ^bShenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Boulevard, Shenzhen 518055, China.

Contents

1. General information	S2
2. General procedure for Rh-catalyzed asymmetric arylation reaction	S2
3. Gram-scale synthesis of 3b	S8
4. The synthesis of 4a	S 8
5. Crystal structure of compound 3j	S10
6. NMR spectra	S11
7. HPLC spectra	S27

1. General information

All reactions were carried out in dry solvents under argon atmosphere unless otherwise noted. All solvents were dried and distilled before use according to the standard methods. The progress of all reactions was monitored by thin layer chromatography to ensure that the reactions had reached completion. NMR spectra were recorded on Varian spectrometers (400 MHz for ¹H, and 125 MHz for ¹³C, 375 MHz for ¹⁹F). Chemical shifts are reported in δ (ppm) referenced to an internal SiMe₄ standard for ¹H NMR and chloroform-*d* (δ 77.36) for ¹³C NMR. MS and HRMS were measured in EI or ESI mode, and the mass analyzer type used for HRMS was Magnetic Sector. Chiral HPLC was performed on a JASCO 2000 instrument by using Daicel chiral columns with hexane/*i*-propanol as the eluent at 220 nm. Substrates were prepared according to the literature procedure.

2. General procedure for Rh-catalyzed asymmetric arylation reaction

A solution of substrate 1 (0.10 mmol), 2 (0.20 mmol), $[Rh(coe)_2Cl]_2$ (2.5 mol%, 1.8 mg, 0.005 mmol of [Rh]), ligand L12 (5.5 mol%, 2.9 mg, 0.0055 mmol) in 1 mL of toluene was stirred at ambient temperature for 30 min under argon atmosphere and then aqueous K₃PO₄ (0.10 mL, 1.0 M, 0.10 mmol) was added to the mixture. After being stirred at ambient temperature for 12 h, the solvent was evaporated in vacuo. The desired product **3** was afforded after purification of the residue by column chromatography (PE/EA = 5/1).



(*R*)-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3a**) White solid (98% yield); $[\alpha]_D^{20}$ -6.9 (*c* 1.1, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.91-7.88 (m, 1H), 7.71-7.68 (m, 2H), 7.47-7.46 (m, 1H), 7.37 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 5.15 (s, 1H), 2.35 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 140.4, 135.8, 135.6, 134.2, 132.6, 131.6, 130.4, 127.2, 126.7, 124.8 (q, *J* = 283.25Hz), 122.1, 69.7 (q, *J* = 30.25 Hz), 21.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.2 (s, 3F); HRMS-EI calcd for C₁₅H₁₂O₂NF₃S (M⁺) 327.0535, found 327.0535.



(*R*)-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3b**) White solid (93% yield); $[\alpha]_D^{20}$ -15.9 (*c* 1.0, CHCl₃) for 97% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.92-7.90 (m, 1H), 7.72-7.70 (m, 2H), 7.52-7.47 (m, 3H), 7.44-7.41 (m, 3H), 5.15 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 135.7, 135.6, 135.4, 134.3, 131.7, 130.2, 129.8, 127.3, 126.8, 124.7 (q, *J* = 287.5 MHz), 122.2, 69.9 (q, *J* = 30.25 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -72.1 (s, 3F); HRMS-EI calcd for C₁₄H₁₀O₂NF₃S (M⁺) 313.0379, found 313.0376.



(R)-3-(4-fluorophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3c**).

White solid (91% yield); $[\alpha]_D^{20}$ -10.9 (*c* 1.0, CHCl₃) for 96% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.92-7.90 (m, 1H), 7.73-7.71 (m, 2H), 7.53-7.50 (m, 2H), 7.48-7.46 (m, 1H), 7.12-7.08 (m, 2H), 5.23 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 163.5 (d, *J* = 208.38 Hz), 135.6, 135.1, 134.4, 131.9, 131.4 (d, *J* = 2.88 Hz), 129.6 (d, *J* = 7.00 Hz), 126.6, 124.7 (q, *J* = 236.35 Hz), 122.3, 116.8(d, *J* = 18.12 Hz), 69.4 (q, *J* = 25.62 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -72.4 (s, 3F), -110.6 (m, 1F); HRMS-EI calcd for C₁₄H₉O₂NF₄S (M⁺) 331.0285, found 331.0282.



(R)-3-(4-methoxyphenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3d**).

White solid (91% yield); $[\alpha]_D^{20}$ 1.3 (*c* 0.8, CHCl₃) for 97% ee; ¹H NMR (400 MHz,

CDCl₃) δ 7.91-7.88 (m, 1H), 7.71-7.69 (m, 2H), 7.48-7.46 (m, 1H), 7.40 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.13 (s, 1H), 3.81 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 160.8, 135.8, 135.7, 134.2, 131.6, 128.8, 127.4, 126.7, 124.8 (q, J = 283.12 Hz), 122.1, 115.0, 69.6 (q, J = 30.25 Hz), 55.7; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.3 (s, 3F); HRMS-EI calcd for C₁₅H₁₂O₃NF₃S (M⁺) 343.0485, found 343.0490.



(R)-3-(naphthalen-2-yl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3e**).

Yellow solid (95% yield); $[\alpha]_D^{20}$ -24.8 (*c* 0.5, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.91 (m, 1H), 7.76 -7.67 (m, 6H), 7.49-7.48 (d, *J* = 5.2 Hz, 1H), 5.55 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 139.3, 135.5, 134.5, 134.4, 132.3 (q, *J* = 32.9 Hz), 132.1, 128.0 (q, *J* = 5.5 Hz), 126.6 (q, *J* = 3.8 Hz), 126.5 (q, *J* = 286.3 Hz), 126.4 (d, *J* = 1.1 Hz), 124.5 (q, *J* = 283.5 Hz), 122.4, 26.4 (q, *J* = 30.2 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -63.11 (s, 3F), -72.21 (s, 3F); HRMS-EI calcd for C₁₅H₉O₂NF₆S (M⁺) 381.0258 found 381.0255.



(R)-3-(3-methoxyphenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3f**).

White oil (82% yield); $[\alpha]_D^{20}$ -17.4 (*c* 0.7, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.88-7.86 (m, 1H), 7.69-7.67 (m, 2H), 7.49-7.48 (m, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.09-7.05 (m, 2H), 6.91 (d, *J* = 8.0 Hz, 1H), 5.45 (s, 1H), 3.75 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 160.4, 136.9, 135.6, 135.1, 134.2, 131.7, 130.8, 126.7, 124.7 (q, *J* = 283.38 Hz), 122.1, 119.3, 115.0, 113.8, 69.7 (q, *J* = 30.25 Hz), 55.7; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.1 (s, 3F); HRMS-EI calcd for C₁₅H₁₂O₃NF₃S (M⁺) 343.0485, found 343.0485.



(R)-3-(3-fluorophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3g**).

Yellow oil (87% yield); $[\alpha]_D^{20}$ -18.6 (*c* 0.5, CHCl₃) for 95% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.92-7.90 (m, 1H), 7.74-7.71 (m, 2H), 7.51-7.49 (m, 1H), 7.43-7.37 (m, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.27 (d, *J* = 8.0 Hz, 1H), 7.14-7.10 (m, 1H), 5.45 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 163.2 (d, *J* = 247.12 Hz), 137.7 (d, *J* = 7.12 Hz), 135.6, 134.6, 134.4, 131.9, 131.5 (d, *J* = 8.12 Hz), 126.5, 124.5 (q, *J* = 283.5 Hz), 123.1, 122.3, 117.3 (d, *J* = 20.75 Hz), 115.0 (d, *J* = 24.38 Hz), 69.4 (q, *J* = 30.62 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -72.3 (s, 3F), -109.7 (m, 1F); HRMS-EI calcd for C₁₄H₉O₂NF₄S (M⁺) 331.0285, found 331.0287.



(R)-3-(3-bromophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3h**).

White solid (82% yield); $[\alpha]_D^{20}$ -24.1 (*c* 0.9, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.90 (m, 1H), 7.74-7.72 (m, 2H), 7.68 (s, 1H), 7.56 (dq, *J* = 8.0, 0.8 Hz, 1H), 7.50-7.49 (m, 1H), 7.48-7.46 (m, 1H), 7.29 (t, *J* = 8.0 Hz, 1H), 5.30 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 137.6, 135.7, 134.5, 134.4, 133.5, 132.0, 131.3, 130.4, 126.6, 126.1, 124.5 (q, *J* = 283.5 Hz), 123.8, 122.4, 69.3 (q, *J* = 30.62 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -72.2 (s, 3F); HRMS-EI calcd for C₁₄H₉O₂NBrF₃S (M⁺) 390.9484, found 390.9464.



(*R*)-3-(o-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3i**). White solid (81% yield); $[\alpha]_D^{20}$ -44.8 (*c* 0.8, CHCl₃) for 90% ee; ¹H NMR (400 MHz,

CDCl₃) δ 7.91 (d, J = 8.0 Hz, 1H), 7.79-7.77 (m, 1H), 7.71 (m, 1H), 7.65 (m, 1H), 7.36-7.29 (m, 2H), 7.27-7.25 (m, 1H), 7.16 (d, J = 6.8 Hz, 1H), 5.15 (s, 1H), 1.79 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 138.5, 136.8, 135.9, 134.6, 134.2, 131.6, 131.5, 130.5, 128.7 (q, J = 4.38 Hz), 126.6, 126.1, 125.1 (q, J = 285.50 Hz), 122.1, 70.3 (q, J = 29.00 Hz), 21.0; ¹⁹F NMR (375 MHz, CDCl₃) δ -70.4 (s, 3F); HRMS-EI calcd for C₁₅H₁₂O₂NF₃S (M⁺) 327.0535, found 327.0537.



(*R*)-5-methyl-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1dioxide (**3j**).

White solid (94% yield); $[\alpha]_D^{20}$ 41.3 (*c* 0.6, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.22-7.20 (m, 3H), 5.15 (s, 1H), 2.44 (s, 3H), 2.35 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 145.5, 140.2, 135.9, 133.0, 132.8, 132.6, 130.3, 127.2, 126.7, 124.8 (q, *J* = 236.12 Hz), 121.80, 69.6 (q, *J* = 25.12 Hz), 22.2, 21.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.1 (s, 3F); HRMS-EI calcd for C₁₆H₁₄O₂NF₃S (M⁺) 341.0692 , found 341.0692.



(R)-5-(tert-butyl)-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3k**).

White solid (86% yield); $[\alpha]_D^{20}$ 58.7 (*c* 1.0, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 8.4 Hz, 1H), 7.73 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.52-7.50 (m, 2H), 7.41-7.40 (m, 4H), 5.27 (s, 1H), 1.31 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 158.8, 135.8, 135.4, 133.0, 130.1, 129.7, 129.3, 127.3, 124.6 (q, *J* = 283.38 Hz), 123.2, 121.7, 69.9 (q, *J* = 30.12 Hz), 35.9, 31.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.1 (s, 3F); HRMS-EI calcd for C₁₈H₁₈O₂NF₃S (M⁺) 369.1005, found 369.1023.



(R)-5-(tert-butyl)-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3l**).

Yellow solid (89% yield); $[\alpha]_D^{20}$ 71.6 (*c* 1.1, CHCl₃) for 97% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.4 Hz, 1H), 7.72 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.41 (s, 1H), 7.37 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 5.24 (s, 1H), 2.35 (s, 3H), 1.31 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 158.7, 140.3, 135.6, 133.1, 132.8, 130.4, 129.2, 127.2, 124.9 (q, *J* = 283.38 Hz), 123.2, 121.6, 69.9 (q, *J* = 30.12 Hz), 35.9, 31.4, 21.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.2 (s, 3F); HRMS-EI calcd for C₁₉H₂₀O₂NF₃S (M⁺) 383.1161, found 383.1161.



(R)-5-(tert-butyl)-3-(4-fluorophenyl)-3-(trifluoromethyl)-2,3dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3m**).

Yellow solid (89% yield); $[\alpha]_D^{20}$ 7.0 (*c* 1.1, CHCl₃) for 99% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 8.0 Hz, 1H), 7.74 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.53 - 7.49 (m, 2H), 7.39 (s, 1H), 7.10 (t, *J* = 8.4 Hz, 2H), 5.25 (s, 1H), 1.32 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 163.5 (d, *J* = 249.50 Hz), 158.9, 135.2, 132.9, 131.6 (d, *J* = 3.375 Hz), 129.6 (d, *J* = 6.3 Hz), 129.4, 124.8 (q, *J* = 283.25 Hz), 123.0, 121.8, 116.8 (d, *J* = 21.75 Hz), 69.4 (q, *J* = 30.25 Hz), 36.0, 31.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.3 (s, 3F), -110.7 (m, 1F); HRMS-EI calcd for C₁₈H₁₇O₂NF₄S (M⁺) 387.0911, found 387.0905.



(R)-5-fluoro-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3n**).

Yellow solid (58% yield); $[\alpha]_D^{20}$ -7.500 (*c* 0.8, CHCl₃) for 99% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.90 - 7.87 (dd, *J* = 8.8, 4.8 Hz, 1H), 7.41-7.37 (m, 3H), 7.24 - 7.22 (d, *J* = 8.0 Hz, 2H), 7.12 - 7.10 (d, *J* = 8.0 Hz, 1H), 5.23 (s, 1H), 2.36 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 166.0 (d, *J* = 255.3 Hz), 140.7, 136.7 (d, *J* = 9.4 Hz), 132.0, 131.8, 130.6, 127.1, 124.6 (q, *J* = 285.3 Hz), 124.4 (d, *J* = 9.7 Hz), 119.8 (d, *J* = 23.9 Hz), 114.0 (d, *J* = 26.5 Hz), 69.4 (q, *J* = 30.3 Hz), 21.4; ¹⁹F NMR (375 MHz, CDCl₃) δ -72.2 (s, 3F), -102.0 (m, 1F); HRMS-ESI calcd for C₁₅H₁₀O₂NF₄S ([M-H]⁻) 344.0368, found 344.0372.



(R)-3-(naphthalen-1-yl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**30**).

Yellow solid (60% yield); $[\alpha]_D^{20}$ -114.8 (*c* 0.8, CHCl₃) for 96% ee; ¹H NMR (400 MHz, CDCl₃) δ 8.06 - 7.97 (m, 3H), 7.88 (d, *J* = 8.0 Hz, 1H), 7.72 (t, *J* = 7.2 Hz, 1H), 7.60 - 7.49 (m, 3H), 7.43 (t, *J* = 7.2 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 5.44 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 136.9, 136.4, 135.5, 134.3, 132.4, 131.7, 130.4, 129.9, 128.4 (q, *J* = 4.25 Hz), 127.8, 127.4, 126.42, 126.37, 125.1 (q, *J* = 285.25 Hz), 124.7, 123.8, 122.5, 71.1 (q, *J* = 29.00 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -70.5 (s, 3F); HRMS-EI calcd for C₁₈H₁₂O₂NF₃S (M⁺) 363.0535, found 363.0538.



(R)-3-(naphthalen-2-yl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3p**).

Yellow solid (81% yield); $[\alpha]_D^{20}$ -84.0 (*c* 1.1, CHCl₃) for 98% ee; ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H), 7.93 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.89 -7.82 (m, 3H), 7.74-7.67 (m, 2H), 7.59-7.55 (m, 2H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 5.34 (s, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 135.8, 135.4, 134.3, 133.5, 133.0, 132.4, 131.8, 130.1, 129.1, 128.1, 127.9, 127.6, 127.1, 126.8, 124.9 (q, J = 283.37 Hz), 124.0, 122.2, 70.1 (q, J = 30.50 Hz); ¹⁹F NMR (375 MHz, CDCl₃) δ -71.8 (s, 3F); HRMS-EI calcd for C₁₈H₁₂O₂NF₃S (M⁺) 363.0535, found 363.0537.

3. Gram-scale synthesis of 3b

A solution of substrate **1a** (4.0 mmol, 1.0 g), phenyl boroxine **2b** (8.0 mmol), $[Rh(coe)_2Cl]_2$ (2.5 mol%, 71.8 mg, 0.02 mmol of [Rh]), ligand **L12** (5.5 mol%, 116.6 mg, 0.022 mmol) in 40 mL of toluene was stirred at ambient temperature for 30 min under argon atmosphere and then aqueous K₃PO₄ (4.0 mL, 1.0 M, 4.0 mmol) was added to the mixture. After being stirred at ambient temperature for 12 h, the solvent was evaporated in vacuo. The residue was purified by column chromatography (PE/EA = 5/1) to afford **3b** (1.1 g, 88% yield) as a white solid.

4. The synthesis of 4a

MeI (0.15 mmol, 21.3 mg) was added to a solution of substrate **3b** (0.05 mmol, 16 mg) and anhydrous K_2CO_3 (0.125 mmol, 17.3 mg) in 1 mL MeCN under argon atmosphere. After being stirred at ambient temperature for 4 hours, the mixture was evaporated in vacuo. The residue was purified by column chromatography (PE/EA = 5/1) to afford **4a** (1.6 mg, 99% yield) as a white solid.



(*R*)-2-methyl-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**4a**).

White solid (99% yield); $[\alpha]_D^{20}$ -76.9 (*c* 1.0, CHCl₃) for 97% ee; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 7.6 Hz, 2H), 7.67 - 7.64 (t, *J* = 7.6 Hz, 1H), 7.62 - 7.58 (t, *J* = 7.2 Hz, 1H), 7.40 - 7.38 (m, 5H), 7.31 - 7.29 (d, *J* = 7.2 Hz, 1H), 2.76 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 135.1, 134.3, 133.8, 133.1, 131.3, 129.8, 129.6, 127.9, 126.6, 125.0 (q, *J* = 286.70 Hz), 121.8, 72.6 (q, *J* = 29.00 Hz), 25.9; ¹⁹F NMR (375 MHz, CDCl₃) δ -68.67 (s, 3F); HRMS-ESI calcd for C₁₅H₁₃O₂NF₃S ([M+H]⁺) 328.0619, found 328.0614.

5. Crystal structure of compound 3j



Figure S1. ORTEP representation of compound 3j

Bond precision:	C-C = 0.0036 A		Wavelengt	h=0.71073
Cell:	a=8.6807(9) alpha=90	b=10.5121 beta=90	(12)	c=16.8506(18) gamma=90
Temperature:	173 K			
	Calculated		Reported	l
Volume	1537.7(3)		1537.7(3	- ;)
Space group	P 21 21 21		P 21 21	21
Hall group	P 2ac 2ab		P 2ac 2a	ıb
Moiety formula	C16 H14 F3 N O2	S	C16 H14	F3 N O2 S
Sum formula	C16 H14 F3 N O2	S	C16 H14	F3 N O2 S
Mr	341.34		341.34	
Dx,g cm-3	1.474		1.474	
Z	4		4	
Mu (mm-1)	0.251		0.251	
F000	704.0		704.0	
F000′	704.93			
h,k,lmax	11,13,21		11,13,21	
Nref	3543[2034]		3519	
Tmin,Tmax	0.939,0.963		0.663,0.	746
Tmin'	0.914			
Correction metho AbsCorr = MULTI	od= # Reported T -SCAN	Limits: T	min=0.663	Tmax=0.746
Data completene:	ss= 1.73/0.99	Theta(m	nax)= 27.5	516
R(reflections)=	0.0344(3296)	wR2(ref	lections)	= 0.0923(3519)
S = 1.050	Npar=	214		



6. NMR spectra



145 135 125 115 105 95 85 75 65 55 45 35 25 15 5 0























































-25.937



7. HPLC Spectra



(*R*)-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3a**) HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 13.0 min,18.2 min (major), 98% ee.





(*R*)-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3b**) HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 12.5 min,15.8 min (major), 97% ee.





(R)-3-(4-fluorophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (3c)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 13.2 min (major),15.9 min, 96% ee.



Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		12.473	33095,145	597479.438	2,2116
2		16.308	1018406.125	26418224.000	97.7884
Total			1051501.270	27015703.438	100.0000



(R)-3-(4-methoxyphenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (3d)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 16.0 min, 27.6 min (major), 97% ee.





(*R*)-3-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3e**)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 11.1 min, 11.8 min (major), 98% ee.







PDA Chi 220nm				
Peak No.	Ret Time	Height	Area	Conc.
1	11.082	4601	119335	1.067
2	11.819	378832	11069880	98.933



(R)-3-(3-methoxyphenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3f**)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 14.8 min, 18.9 min (major), 98% ee.





(R)-3-(3-fluorophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3g**)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 10.2 min, 13.7 min (major), 95% ee.





(R)-3-(3-bromophenyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3h**)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 10.6 min, 13.2 min (major), 98% ee.





2

Peak ID

Peak No.

1

2 Total 4

6

Ret Time

12.547

17.190

8

(*R*)-3-(o-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3i**) HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 12.5 min, 17.2 min (major), 90% ee.



S45	

10 12 Time(min)

Height

27209.775

348888.188

376097.963

Results

14

16

20

22

Conc.

5.2422

94.7578

100.0000

18

Area

575848.375

10409069.000

10984917.375



(R)-5-methyl-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1dioxide (3j)

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 16.3 min, 23.1 min (major), 98% ee.



502098.706 Total



(R)-5-(tert-butyl)-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3k**):

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 15.2 min, 21.0 min (major), 98% ee.





(*R*)-5-(tert-butyl)-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3**l):

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 17.2 min, 26.1 min (major), 99% ee.



 2
 26.093
 852128.313
 38670804.000
 99.4050

 Total
 861162.735
 38902268.859
 100.0000



(*R*)-5-(tert-butyl)-3-(4-fluorophenyl)-3-(trifluoromethyl)-2,3dihydrobenzo[*d*]isothiazole 1,1-dioxide (**3m**):
HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20;
flow = 0.5 mL/min; Retention time: 12.8 min, 17.4 min (major), 99% ee.



Total

1140853.907

32851895.406

100.0000



(R)-5-fluoro-3-(p-tolyl)-3-(trifluoromethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (**3n**):

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 13.6 min, 16.6 min (major), 99% ee.







(*R*)-3-(naphthalen-1-yl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**30**):

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 14.8 min, 17.1 min (major), 96% ee.





(R)-3-(naphthalen-2-yl)-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1dioxide (**3p**) HBLC: Chiralack IC column (250 mm): detected at 220 nm; hoveno/*i* propagal = 80/20;

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 80/20; flow = 0.5 mL/min; Retention time: 16.6 min, 25.8 min (major), 98% ee.





100.0000



(*R*)-2-methyl-3-phenyl-3-(trifluoromethyl)-2,3-dihydrobenzo[*d*]isothiazole 1,1-dioxide (**4a**).

HPLC: Chiralpak IC column (250 mm); detected at 220 nm; hexane/*i*-propanol = 95/5; flow = 0.5 mL/min; Retention time: 55.2 min, 58.1 min (major), 97% ee.



